-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
iTeos Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2020 to 2023.
- iTeos Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending September 30, 2024 was -1.05 USD/shares, a 16.7% decline year-over-year.
- iTeos Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending September 30, 2024 was -3.15 USD/shares, a 81% decline year-over-year.
- iTeos Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -3.15 USD/shares, a 223% decline from 2022.
- iTeos Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was 2.56 USD/shares, a 54.9% decline from 2021.
- iTeos Therapeutics, Inc. annual Earnings Per Share, Diluted for 2021 was 5.68 USD/shares.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)